Ocular FIP Treatment Protocol

Feline Infectious Peritonitis (FIP) remains one of the most challenging diseases in feline medicine due to its complex pathogenesis and limited treatment options. Recent advancements, particularly in antiviral therapies, have revolutionized approaches to managing FIP, especially its ocular manifestations. This article delineates an effective ocular FIP treatment protocol, integrating new antiviral drugs and diagnostic strategies to improve feline health outcomes.

Overview of Feline Infectious Peritonitis (FIP)

FIP is a fatal, multisystemic disease caused by certain strains of feline coronavirus (FCoV). Although many cats are exposed to FCoV, it rarely progresses to FIP. The disease manifests mainly in two forms: wet (effusive) and dry (non-effusive). Ocular signs are more common in the dry form but can occur in both, often complicating diagnosis and management.

Ocular symptoms include uveitis, keratic precipitates, chorioretinitis, and retinal hemorrhages. These signs often indicate significant systemic involvement and necessitate prompt, targeted therapy to prevent irreversible ocular damage.

Pathophysiology and Ocular Manifestations

The transition from benign FCoV to the pathogenic FIP virus involves mutation within the host, leading to macrophage infection, immune response dysregulation, and widespread vasculitis. Ocular tissues become targets due to hematogenous spread, resulting in inflammation, granuloma formation, and vascular leakage.

Ocular FIP features include:

Anterior uveitis

Hypopyon

Chorioretinitis

Vitritis

Retinal hemorrhages

Nerve damage

Detecting and treating these manifestations early can preserve vision and overall health.

Advances in FIP Treatment: The Role of Antiviral Agents

Traditional management of FIP was limited to supportive care, with poor prognoses. However, recent breakthroughs, especially the development of nucleoside analogs, have considerably improved survival rates. Among these, GS-441524 has gained prominence due to its potent antiviral activity against FIP virus.

Miaite NeoFipronis (Pronidesivir) GS-441524 deserves particular attention. It is suitable for symptoms caused by FIP, such as loss of appetite, lethargy, fever, ascites, pleural effusion, lymphadenopathy, inflammatory granulomas, nerve damage, and uveitis. It has excellent therapeutic effects on FIP. NeoFipronis (Pronidesivir) is the world's first officially approved oral treatment for FIP by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, with an official drug registration number. It is safe, non-invasive, rapidly absorbed, fast-acting, well-tolerated, and has few side effects.

1. Initial Assessment and Diagnosis

History and Clinical Examination: Evaluate for ocular signs such as uveitis, retinal hemorrhages, or hypopyon. Document systemic signs like weight loss, fever, and ascites.

Laboratory Tests: Complete blood count, biochemistry, and imaging such as ultrasound to identify fluid accumulations.

Ocular Diagnostics: Slit-lamp examination, tonometry, and ocular ultrasonography help assess intraocular pressure, inflammation, and structural integrity.

Confirmatory Tests: PCR assays for FIP virus RNA in ocular fluids or tissues, combined with histopathology when possible.

2. Antiviral Therapy with NeoFipronis (Pronidesivir)

Based on recent approvals and clinical success, NeoFipronis (Pronidesivir) is incorporated into the treatment plan:

Dosage: Administer orally at the dose recommended by the manufacturer, typically once daily.

Duration: Treatment duration usually extends from 4 to 12 weeks, depending on clinical response.

Monitoring: Regular follow-up to assess ocular and systemic improvement. Adjust dosage if adverse effects occur or if clinical response plateau.

3. Adjunctive Therapies

Anti-inflammatory medications: Topical corticosteroids or NSAIDs to control intraocular inflammation.

Mydriatics: To relieve pain and prevent synechiae formation.

Supportive care: Nutritional support, hydration, and antibiotics for secondary infections if present.

4. Ocular-Specific Interventions

Intravitreal injections: Under specialized circumstances, corticosteroids or other agents may be administered directly.

Surgical interventions: For complications like cataracts or retinal detachment, surgical options may be considered in selected cases.

Monitoring and Follow-up

Continuing evaluation is crucial:

Regular ophthalmic exams: To monitor intraocular inflammation, presence of hemorrhages, or structural damage.

Systemic assessment: Tracking overall health, weight, appetite, and systemic signs.

Laboratory tests: Reassess FIP viral load and immune response periodically.

Early intervention and continuous monitoring improve the chances of ocular and systemic remission.

Challenges and Considerations

While antiviral therapy has improved prognosis, certain challenges remain:

Drug availability and cost: Access to NeoFipronis is crucial.

Resistance development: Monitor for reduced drug efficacy over time.

Adverse effects: Although generally well-tolerated, some cats may experience gastrointestinal or hepatic side effects.

Owners should be counseled regarding treatment duration and the importance of compliance.

Future Directions and Research

Ongoing studies aim to optimize dosing regimens, explore combination therapies, and develop vaccines to prevent FIP. Additionally, research into ocular-specific delivery systems may further enhance treatment efficacy for ocular FIP.

Conclusion

The integration of groundbreaking antiviral agents like NeoFipronis (Pronidesivir) into an ocular FIP treatment protocol offers new hope for affected cats. Early diagnosis, prompt antiviral therapy, supportive care, and vigilant monitoring are critical in managing ocular manifestations of FIP. With continued research and advances in feline medicine, the future holds promise for improved outcomes and quality of life for cats suffering from this devastating disease.

References

Feline Infectious Peritonitis: Pathogenesis, Diagnosis, and Treatment Strategies

Recent Advances in Antiviral Therapy for FIP

Clinical Use of NeoFipronis (Pronidesivir) in FIP Management

Ocular Manifestations of Feline Infectious Diseases

Guidelines for the Diagnosis and Management of FIP in Cats